A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A
Study Details
- Hemophilia A, Acquired
- Drug: Bometase Alfa
- Age ≥18 years;
- Confirmed diagnosis of acquired hemophilia A, meeting the following criteria:
- Isolated prolongation of activated partial thromboplastin time (APTT) with a normal prothrombin time (PT);
- Reduced factor VIII coagulant activity (FVIII:C \<50%);
- Positive FVIII inhibitor, defined as ≥0.6 BU/mL as measured by the Bethesda assay or Nijmegen-modified Bethesda assay, or failure of a 1:1 mixing study with normal plasma to achieve complete correction;
- No evidence of congenital hemophilia, von Willebrand disease, or lupus anticoagulant;
- Presence of clinically significant active bleeding, including, but not limited to, muscle or subcutaneous hematoma, gastrointestinal or genitourinary bleeding, postpartum or postoperative bleeding, or deep-seated or life-threatening organ bleeding;
- Provision of written informed consent by the patient and/or a legally authorized representative;
- Ability to comply with the study follow-up schedule for at least 30 da
- Congenital hemophilia A or B, or any other confirmed congenital coagulation factor deficiency;
- Isolated prolonged activated partial thromboplastin time (APTT) due to lupus anticoagulant or antiphospholipid syndrome, with a negative FVIII inhibitor and normal FVIII activity; or coagulation abnormalities caused by disseminated intravascular coagulation (DIC) or severe liver disease that do not fulfill the diagnostic criteria for acquired hemophilia A;
- A history or symptoms of any arterial or venous thromboembolic event within 3 months before enrollment, including atherosclerosis, myocardial infarction, ischemic stroke, transient ischemic attack, deep vein thrombosis, or pulmonary embolism, or the presence of DIC;
- Use of factor VII (FVII), activated factor VII (FVIIa), tranexamic acid, or aminocaproic acid within 1 day before the planned administration of the study drug; or use of prothrombin complex concentrate (PCC) or factor VIII (FVIII) within 3 days before the first administration;
- Female participants who are pregnant or breastfeeding, or have a positive pregnancy test;
- Known hypersensitivity to the investigational product or any of its excipients;
- Inability to obtain informed consent, including patients unable to express their wishes and without a legally authorized representative;
- Inability to comply with the study follow-up requirements or investigator-determined poor compliance;
- Any other condition for which the investigator considers the participant unsuitable for study participation.
Protocol Summary
This study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector. The participants can choose themselves, in collaboration with the study doctor how often they get Mim8 in this study. When the participant will get their first Mim8 injection depends on their current treatment with emicizumab. The participants will get their first Mim8 injection at Visit 2. Participants will have between 6 and 27 Mim8 injections. The total number of injections participants will have depends on their dosing frequency. The study will last for about 6-12 months. While taking part in this study, there are some restrictions about what medicine participant can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.